gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.
Company profile
Ticker
GANX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
851726310
GANX stock data
Latest filings (excl ownership)
8-K
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
8 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
26 Mar 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Gain Therapeutics’ Ceo Matthias Alder Issues Letter to Shareholders and Provides Operational Update
31 Jan 24
424B3
Prospectus supplement
2 Jan 24
EFFECT
Notice of effectiveness
2 Jan 24
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
S-1
IPO registration
19 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.30 mm | 4.30 mm | 4.30 mm | 4.30 mm | 4.30 mm | 4.30 mm |
Cash burn (monthly) | 682.70 k | 550.42 k | 1.63 mm | 1.87 mm | 1.32 mm | 1.43 mm |
Cash used (since last report) | 4.67 mm | 3.77 mm | 11.14 mm | 12.79 mm | 9.05 mm | 9.75 mm |
Cash remaining | -366.56 k | 538.30 k | -6.84 mm | -8.49 mm | -4.74 mm | -5.45 mm |
Runway (months of cash) | -0.5 | 1.0 | -4.2 | -4.5 | -3.6 | -3.8 |
Institutional ownership, Q2 2023
7.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 11 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 5.06 bn |
Total shares | 1.27 mm |
Total puts | 22.20 k |
Total calls | 30.30 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Greenlight Capital | 546.56 k | $2.45 bn |
Geode Capital Management | 138.72 k | $621.47 mm |
CM Management | 90.00 k | $403.00 k |
Susquehanna International | 69.79 k | $312.66 mm |
Vanguard | 64.12 k | $287.25 mm |
Prelude Capital Management | 58.10 k | $260.29 mm |
Renaissance Technologies | 47.60 k | $213.00 k |
Bridgeway Capital Management | 46.10 k | $206.53 mm |
Citadel Advisors | 36.25 k | $162.39 mm |
Raymond James & Associates | 33.40 k | $149.63 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Gene Mack | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.56 | 200,000 | 712.00 k | 200,000 |
28 Mar 24 | Jeffrey Scott Riley | Common Stock | Buy | Acquire P | No | No | 3.859 | 30,000 | 115.77 k | 30,000 |
26 Mar 24 | Matthias Alder | Common Stock | Payment of exercise | Dispose F | No | No | 4.06 | 6,085 | 24.71 k | 21,140 |
26 Mar 24 | Matthias Alder | Common Stock | Option exercise | Acquire M | No | No | 0 | 637 | 0.00 | 27,225 |
26 Mar 24 | Matthias Alder | Common Stock | Option exercise | Acquire M | No | No | 0 | 825 | 0.00 | 26,588 |
26 Mar 24 | Matthias Alder | Common Stock | Option exercise | Acquire M | No | No | 0 | 18,750 | 0.00 | 25,763 |
26 Mar 24 | Matthias Alder | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 637 | 0.00 | 6,376 |
26 Mar 24 | Matthias Alder | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 825 | 0.00 | 8,250 |
26 Mar 24 | Matthias Alder | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 18,750 | 0.00 | 56,250 |
21 Mar 24 | Gianluca Fuggetta | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 50,000 | 218.50 k | 50,000 |
News
Gain Therapeutics Reports Results From Single Ascending Dose Part Of Phase 1 Clinical Trial Of GT-02287, Novel GCase-Targeting Small Molecule Therapy For GBA1 Parkinson's Disease
24 Apr 24
Oppenheimer Maintains Outperform on Gain Therapeutics, Maintains $9 Price Target
23 Apr 24
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
2 Apr 24
Chardan Capital Reiterates Buy on Gain Therapeutics, Maintains $6 Price Target
27 Mar 24
Gain Therapeutics Q4 EPS $(0.29) Beats $(0.32) Estimate
26 Mar 24
Press releases
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease
24 Apr 24
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
8 Apr 24
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
1 Apr 24
Gain Therapeutics to Present at Public Ventures Discovery Day
15 Mar 24
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease
27 Feb 24